Skip to content

Hsinchu Science Park_logo

Hot KeyWords: Responsibilities & Duties, Statistics Annually, List of Companies │ Classified Query

Language
×
:::
Print

Innovative Product Awards

* Company Data:
Date of Registration:
Address:
Tel:
Fax:
Web Site:
* Company Profile :

GWOXI Stem Cell Applied Technology Co., Ltd. was established, on March 31st in 2004, on basis of its applied stem cell technology to innovate new applications in regenerative and preventive medicines, set up health-examination platforms, and develop innovative stem cell drug. Since stem cells are the major source of cell or tissue biogenesis, they bring hopes for diseases curing. Applied stem cell research is becoming the main stream of future pharmaceutical and therapeutic development. GWOXI has not only been cultivating in applied stem cell research for a long time, but also bringing together resources in industry, government, academics and medicine in hoping to benefit all human being to the most extend.
In 2010, GWOXI was granted for its “applied stem cell technology in treating cirrhosis/fibrosis” by National Science Council of Taiwan to establish a GTP-standard stem cell R&D center in Biomedical Science Park in Hsinchu Country. GWOXI then became one of government-support biotechnology and pharmaceutical companies after passing through the Act for the Development of Biotech and New Pharmaceuticals Industry under Industrial Development Bureau of Ministry of Economic Affairs in 2012. In 2018, GWOXI not only extended the period of support but also applied two new drugs into clinical trials successfully, including GXNPC1.
Innovation Product
Cerebrovascular disease is one of the top ten causes of death in Taiwan. Once a stroke is not treated within a certain period of time, it will cause different degrees of disability, and only passive rehabilitation can be done without other effective treatment methods. The long-term care needs caused by stroke and lost work due to disability will cause a serious burden on the caregiver's psychology and family economy. The new drug, GXNPC1, has capacity to promote cerebral blood vessels and nerves regenerate. It has been confirmed by animal experiments that can improve the disability caused by stroke and increase the coordination, balance and activity ability. GXNPC1 provide new hope for chronic stroke patients.

Formulated of GXNPC1 by GWOXI for the treatment of chronic strokes been licensed five invention patent in Taiwan or American within three years in 2016-2018. In 2016, it has been approved Phase I clinical trials in Hualien Tzu Chi Hospital by Ministry of Health and Welfare.The first stem cell intracerebral transplantation was completed in 2017 and clinical trial patient reception had completed in May 2018.

* Innovation Product:
    

1. Customized stem cell preparations (Safety, Quality, Certification)
2. Comprehensive restoration of cerebrovascular and nerve (Immunity, Regeneration, Replace)
3. First, intracerebral transplantation of the autologous adipose-derived stem cells in Taiwan (Science, Regulation, Clinical)

*R&D Engineers:

Previous TOP